Module 1 2021

 Manufacturers and governments working to explore new approaches to timely coverage for high cost therapies:  End-of life therapies  Orphan drugs / orphan diseases  Risk sharing  Coverage with evidence development  Value-based assessment / value-based pricing Alternative approaches

49

Pharmaceutical life-cycle

50

25